OTC Markets OTCPK - Delayed Quote USD

HUTCHMED (China) Limited (HMDCF)

Compare
3.8150
0.0000
(0.00%)
At close: December 2 at 3:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for HMDCF

Recent News: HMDCF

View More
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
GlobeNewswire 17 days ago
Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week
Simply Wall St. 25 days ago
Hutchmed divests 45% interest in Shanghai Hutchison for $608M

Hutchmed divests 45% interest in Shanghai Hutchison for $608M
TipRanks 28 days ago
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
GlobeNewswire 29 days ago
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
GlobeNewswire 29 days ago
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
GlobeNewswire last month
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy
GlobeNewswire last month
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
PR Newswire last month
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer
GlobeNewswire last month
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
GlobeNewswire 2 months ago
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
GlobeNewswire 2 months ago
View More

Related Tickers

CASBF CanSino Biologics Inc.
3.3740
0.00%
 
HLBBF H. Lundbeck A/S
5.60
0.00%
 
NPPNY Nippon Shinyaku Co., Ltd.
6.08
0.00%
 
HLNCF Haleon plc
4.7700
+0.21%
 
IGPK Integrated Cannabis Solutions, Inc.
0.0042
-4.55%
 
ALVO Alvotech
12.41
-1.27%
 
IRWD Ironwood Pharmaceuticals, Inc.
2.3000
-38.17%
 
ALKS Alkermes plc
31.91
+1.11%
 
MDP.TO Medexus Pharmaceuticals Inc.
3.9900
-0.25%
 
ELAN Elanco Animal Health Incorporated
12.47
+1.46%